Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

David R. Matthews, J P Hosker, A. Rudenski et al. · Diabetologia · 1985 · 31.4K citations · Full text

Medicine, Endocrinology, Physiology +17

U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

Diabetes · 1995 · 1.9K citations

Medicine, Endocrinology, Internal Medicine +17

GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN

Bernhard Kreymann, Mohammad A. Ghatei, Gareth Williams et al. · The Lancet · 1987 · 1.9K citations

Life Sciences, Endocrinology, Physiology +10

Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

Michael A. Nauck, F. Stöckmann, R. Ebert et al. · Diabetologia · 1986 · 1.3K citations · Full text

Medicine, Endocrinology, Pharmacology +13

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Michael A. Nauck, N. Kleine, C. �rskov et al. · Diabetologia · 1993 · 1.1K citations · Full text

Medicine, Endocrinology, Internal Medicine +15